Published OnlineFirst May 14, 2013; DOI: 10.1158/0008-5472.CAN-12-4297

Cancer
Research

Therapeutics, Targets, and Chemical Biology

KEAP1 Is a Redox Sensitive Target That Arbitrates the
Opposing Radiosensitive Effects of Parthenolide in Normal
and Cancer Cells
Yong Xu1, Fang Fang2, Sumitra Miriyala1, Peter A. Crooks3, Terry D. Oberley4, Luksana Chaiswing4, Teresa
Noel1, Aaron K. Holley1, Yanming Zhao1, Kelley K. Kiningham5, Daret K. St. Clair1, and William H. St. Clair2

Abstract
Elevated oxidative stress is observed more frequently in cancer cells than in normal cells. It is therefore
expected that additional exposure to a low level of reactive oxygen species (ROS) will push cancer cells toward
death, whereas normal cells might maintain redox homeostasis through adaptive antioxidant responses. We
previously showed that parthenolide enhances ROS production in prostate cancer cells through activation of
NADPH oxidase. The present study identiÔ¨Åes KEAP1 as the downstream redox target that contributes to
parthenolide's radiosensitization effect in prostate cancer cells. In vivo, parthenolide increases radiosensitivity of
mouse xenograft tumors but protects normal prostate and bladder tissues against radiation-induced injury.
Mechanistically, parthenolide increases the level of cellular ROS and causes oxidation of thioredoxin (TrX) in
prostate cancer cells, leading to a TrX-dependent increase in a reduced state of KEAP1, which in turn leads to
KEAP1-mediated PGAM5 and Bcl-xL (BCL2L1) degradation. In contrast, parthenolide increases oxidation of
KEAP1 in normal prostate epithelial cells, leading to increased Nrf2 (NFE2L2) levels and subsequent Nrf2dependent expression of antioxidant enzymes. These results reveal a novel redox-mediated modiÔ¨Åcation of
KEAP1 in controlling the differential effect of parthenolide on tumor and normal cell radiosensitivity. Furthermore, they show it is possible to develop a tumor-speciÔ¨Åc radiosensitizing agent with radioprotective properties
in normal cells. Cancer Res; 73(14); 4406‚Äì17. 2013 AACR.

Introduction
It is well documented that cancer cells are usually under
more oxidative stress than normal cells are, in part, due to a
hyperactive metabolism that fuels their rapid growth (1, 2).
Thus, a therapy designed to increase reactive oxygen species
(ROS) to a level above the threshold for cancer cell death, but to
an adaptable level for normal cells, would be an attractive
strategy to selectively kill cancer cells (3, 4). Redox homeostasis
is thought to regulate many cellular processes that are essential
for maintenance of normal physiologic conditions but is
aberrantly modulated in cancers (5, 6). The functions of
ROS are both beneÔ¨Åcial and deleterious due to their dual role
in the prosurvival and antisurvival pathways. As a secondary
messenger in cell signaling, ROS are required for normal
development and can initiate adaptive responses in cellular
Authors' AfÔ¨Åliations: 1Graduate Center for Toxicology, 2Department of
Radiation Medicine, University of Kentucky, Lexington, Kentucky; 3Department of Pharmaceutical Sciences, UAMS College of Pharmacy, Little Rock,
Arkansas; 4Department of Pathology, University of Wisconsin, Madison,
Wisconsin; and 5Department of Pharmaceutical Sciences, Belmont University School of Pharmacy, Nashville, Tennessee
Corresponding Authors: William H. St. Clair, Department of Radiation
Medicine, University of Kentucky, College of Medicine, Lexington, KY
40536. Phone: 859-257-4931; Fax: 859-323-6486; E-mail:
stclair@uky.edu; and Daret K. St. Clair, E-mail: dstcl00@uky.edu
doi: 10.1158/0008-5472.CAN-12-4297
2013 American Association for Cancer Research.

4406

defense (7, 8). On the other hand, ROS cause structural damage
and functional decline in DNA, proteins, and lipids, and
consequently act as an antitumorigenic factor by inducing
cell senescence and apoptosis (9, 10). Indeed, ROS-mediated
cell death is an important basis for radiotherapy and many
chemotherapeutic treatments (11, 12). Currently, these therapeutic strategies are being used to kill cancer cells without
beneÔ¨Åt of a rational design that exploits the intrinsic differences in the cellular redox status of normal cells and cancer
cells.
Antioxidant defense systems are essential for the regulation of ROS levels, which have an important function in the
maintenance of cellular redox hemostasis. Mounting evidence shows that a decline in antioxidant function may be
involved in tumorigenesis due to prooxidant conditions that
result from ROS accumulation. For example, manganese
superoxide dismutase (MnSOD) is downregulated in many
types of cancer and overexpression of MnSOD results
in suppression of tumorigenesis (13‚Äì15). High levels of
antioxidants caused by therapy-mediated activation of
prosurvival pathways, such as NF-kB and Nrf2, are thought
to protect cancer cells against treatment (16‚Äì18). Thus,
inhibition of prosurvival pathways has been a traditional
strategy to enhance therapeutic efÔ¨Åcacy.
Increasing evidence shows that certain mild prooxidant
compounds derived from natural herbal medicines might
enhance some anticancer treatments by modulating the

Cancer Res; 73(14) July 15, 2013

Downloaded from cancerres.aacrjournals.org on September 2, 2017. ¬© 2013 American Association for Cancer Research.

Published OnlineFirst May 14, 2013; DOI: 10.1158/0008-5472.CAN-12-4297

Keap1, a Central Regulator of Cellular Redox Signaling

redox state of cancer cells to high prooxidant levels (19, 20).
Parthenolide, an active ingredient derived from the traditional anti-inÔ¨Çammatory medical plant feverfew (Tanacetum
parthenium), belongs to the family of sesquiterpene lactones
containing an a-methylene-g-lactone moiety and an epoxide
group, which is able to conjugate thiols of proteins through a
Michael addition reaction (21). In addition to its antiinÔ¨Çammatory effect, parthenolide seems to be toxic to a
variety of cancer cells (22‚Äì25). Importantly, parthenolide has
no cytotoxic effect on normal cells (25). Mechanistically,
parthenolide has been shown to increase apoptosis in cancer
cells through inhibition of multiple prosurvival pathways,
such as NF-kB and PI3K-AKT (19, 26). However, these
Ô¨Åndings do not explain why parthenolide is not toxic to
normal cells.
Posttranslational modiÔ¨Åcation is a key mechanism by which
proteins dramatically increase their functional diversity.
Reversible redox modiÔ¨Åcation of protein cysteine residues
plays an important role in vital cell signaling pathways related
to many physiologic and pathogenic processes (27, 28). The
Keap1-Nrf2 pathway is one of the main cellular defense
mechanisms against oxidative stress (29, 30). The present study
examines the role of cysteine modiÔ¨Åcations in modulating
radiation responses in prostate cancer cells versus normal
prostate epithelial cells. It elucidates the functional link
between redox modulation and cell signaling transduction
pathways, and it provides evidence for the differential effect
of parthenolide on cellular redox status in normal and cancer
cells. The results reveal that parthenolide-mediated redox
modiÔ¨Åcation of Keap1 serves as a central regulator of differential responses to radiotherapy in normal and tumor cells.
The present study provides a proof-of-concept for using an
intrinsic difference in cellular redox conditions to kill tumor
cells while protecting normal cells from the unwanted side
effects of radiation.

Materials and Methods
Cell culture, cell transfection, treatment, and cell
survival analysis
Human prostate carcinoma/adenocarcinoma LNCaP,
PC3, and DU145 cell lines as well as human prostate epithelial viral transformed PZ-HPV-7 (PZ) and RWPE-1 cell
lines were obtained from American Type Culture Collection.
Normal prostate epithelial PrEC cells were purchased from
Lonza. All cell lines were cultured and maintained in the
media recommended in the manufacturer's protocols.
Plasmid-cloned Keap1 cDNA and Bcl-xL cDNA (OriGene)
and siRNAs for knocking down Keap1, Nrf2, thioredoxin
(TrX), PGAM5, and Bcl-xL (Dharmacon) were transfected
into cultured cells before treatment. Parthenolide and
its water-soluble prodrug, dimethylamino-parthenolide
(DMAPT), were synthesized as previously described (31).
The cells were treated with 0 to 5 mmol/L parthenolide
followed by irradiation by a 250 kV X-ray machine (Faxitron
X-ray Corp.) with peak energy of 130 kV, 0.05 mm Al Ô¨Ålter, at
a dose of 0 to 6 Gy. Cell survival rates were quantiÔ¨Åed by
colony survival fraction, Trypan blue exclusion assay, and
MTT assay, as previously described (25, 32).

www.aacrjournals.org

Animals
Four- to Ô¨Åve-week-old male NCRNU (nu/nu athymic nude)
mice were obtained from Taconic (Hudson). For formation of
xenograft tumors, 1.8  106 cells mixed in Matrigel (BD
Biosciences) were subcutaneously injected into the right Ô¨Çank
of the mice. Tumor volumes were routinely measured and their
sizes calculated on the basis of a protocol described elsewhere
(33). Animals with an average tumor size of 500 mm3 were
randomized into several groups for DMAPT and radiation
treatments. The tumors were treated 5 times with 10 mg/kg
DMAPT and 3 Gy IR. The tumor tissues were collected, and 100
mg of tissue was lysed to quantify amounts of oxidized or
reduced Keap1 and levels of downstream proteins. To determine the protective effect of parthenolide against radiation
damage, mice were pretreated with DMAPT followed by radiation treatment (5  3Gy). Prostate and bladder tissues were
Ô¨Åxed, embedded, and processed for routine electron microscopy. The embedded blocks were sectioned and transferred to
copper grids and counterstained with uranyl acetate, followed
by lead citrate. Grids were observed in an electron microscope
(Hitachi H-600) operated at 75 kV. Mitochondrial damage was
quantiÔ¨Åed by a pathologist (T.D. Oberley) using identiÔ¨Åed
ultrastructural changes including swelling, vacuolization,
myelination, disorganization, and loss of cristae, lysosomal
degradation, and membrane disruption. Animal experimental
procedures were approved by the Institutional Animal Care
and Use Committee of the University of Kentucky (Lexington,
KY), Approval Protocol No. 01077M2006.
QuantiÔ¨Åcation of intracellular superoxide and
prooxidant
Dihydroethidium (DHE, Invitrogen), which exhibits blue Ô¨Çuorescence in the cytosol until oxidized, was used to estimate the
levels of superoxide after parthenolide treatment. To conÔ¨Årm the
level of superoxide induced by parthenolide, the cells were pretreated with 50 mg PEG-SOD (Sigma) for 1 hour followed by
parthenolide treatment. Antimycin (Sigma) was used as a positive control because it has been shown to increase superoxide in
all tested cell lines. A dichloroÔ¨Çuorescein (DCF) assay was used
to quantify the levels of intracellular ROS after parthenolide
treatment. The cells were labeled by both carboxy-H2DCFDA
(sensitive to oxidation, Invitrogen) and carboxy-DCFDA (insensitive to oxidation, Invitrogen). The H2DCFDA:DCFDA ratio was
used to optimize the controls of cell number, dry uptake, and
ester cleavage. The procedures for both DHE and DCF were
conducted by the University of Kentucky Flow Cytometer Facility
using a FACScan protocol provided by Dr. Douglas R. Spitz
(Professor of Radiation Oncology at the University of Iowa; 34).
Measurement of oxygen consumption rates
To determine how parthenolide changes mitochondrial
function in cancer and normal cells, a Seahorse Bioscience
XF24 Extracellular Flux Analyzer was used to measure oxygen
consumption rates (OCR) after parthenolide treatment. The
XF24 creates a transient, 7 mL chamber in specialized microplates, which allows determination of oxygen and proton
concentrations in real time. To allow comparison between
experiments, data are expressed as the OCR in pmoL/min or

Cancer Res; 73(14) July 15, 2013

Downloaded from cancerres.aacrjournals.org on September 2, 2017. ¬© 2013 American Association for Cancer Research.

4407

Published OnlineFirst May 14, 2013; DOI: 10.1158/0008-5472.CAN-12-4297

Xu et al.

the rate of extracellular acidiÔ¨Åcation in mpH/min. Reserve
capacity, an important index that indicates capacity of mitochondrial respiration, is calculated by subtracting baseline
OCR from maximal OCR.
Detection of oxidized and reduced forms of Keap1
protein
3-N-maleimido-propionyl biocytin was used to selectively
label sulfhydryl (SH) and then was detected by biotin‚Äìstreptavidin integration on the blots, as previously described (35).
To quantify disulÔ¨Åde (S-S) bonds, the SH form was stabilized by
treating with N-ethylmaleimide and then the S-S bonds were
reduced by treating with 2-mercaptoethanol. To identify SH
and S-S moieties of Keap1 protein, the labeled proteins were
immunoprecipitated by Keap1 antibody (Abcam) and subjected to SDS-PAGE, followed by detection with horseradish
peroxidase-conjugated streptavidin (Sigma).
Immunoblots and immunoprecipitation
Homogenized cells and tumor tissues were electrophoresed
on an 8% (w/v) SDS-PAGE gel, transferred onto a nitrocellulose
membrane, and subsequently incubated with primary antibodies against Keap1 (Abcam), Nrf2 (Abcam), MnSOD (Upstate
Biotech), CuZnSOD (eBiosci), Gpx (Abcam), catalase (Millipore), TrX (BD Sciences), PGAM5 (Santa Cruz Biotech.), Bcl-xL
(Santa Cruz Biotech.), LC3B (Cell Signaling), b-actin (Sigma),
and pCNA (Santa Cruz Biotech.). All secondary antibodies were
obtained from Santa Cruz Biotech. Immunoblots were visualized using an enhanced chemiluminescence detection system
(Amersham Pharmacia Biotech.). For immunoprecipitation,
cell extracts were incubated overnight with one primary antibody at 4 C and integrated with a protein A/G agarose (Santa
Cruz Biotech). Immunocomplexes were precipitated and fractionated on an SDS-PAGE gel. Interacting proteins were
detected by immunoblotting with their primary antibodies.
SOD enzymatic assay
MnSOD activities were measured by the nitroblue tetrazolium-bathocuproin sulfonate reduction inhibition method.
Sodium cyanide (2 mmol/L) was used to inhibit CuZnSOD
activity (36).
Statistical data analyses
Multiple independent experiments were conducted for each
set of data presented. Images in Immunoblots were quantiÔ¨Åed
using Carestream Molecular Imaging software (Carestream
Health Inc.). Statistical signiÔ¨Åcance was analyzed using oneway ANOVA and Tukey multiple comparison test, followed by
data analysis with GraphPad Prism.

Results
Parthenolide enhances radiosensitivity of prostate
tumors but protects normal tissues from radiation
Our previous studies showed that parthenolide is able to
selectively enhance the radiosensitivity of prostate cancer cells
without injury to normal prostate epithelial cells (24, 25). To
determine whether parthenolide enhances radiotherapy in
vivo, human prostate cancer PC3 cells were subcutaneously

4408

Cancer Res; 73(14) July 15, 2013

implanted into the right Ô¨Çank of nude male mice. When tumor
size reached a volume of 500 mm3, animals were randomized
into groups according to the treatment consisting of saline or
10 mg/kg DMAPT. One hour after saline or DMAPT was
administered, the tumors were treated with fractionated radiation of 1 Gy or 2 Gy per day for 5 days followed by routine
measurement of tumor volume. The tumor growth curves are
shown in Fig. 1A. Mice were humanely killed when a tumor
reached the maximum size of 2,000 mm3. Tumor growth was
clearly delayed in the treatment groups, particularly when the
drug and radiation were combined, compared with growth in
the untreated group. The tumor growth rates after treatment
were compared according to the days needed for tumor
volume to reach 2,000 mm3. DMAPT signiÔ¨Åcantly enhanced
radiotherapeutic efÔ¨Åciency compared with the effects of radiation treatment alone (Fig. 1B). A separate group of nude male
mice that had no cancer cell implantation was treated with
DMAPT and radiation to determine the toxicity of DMAPT to
organs that can be affected by radiotherapy of prostate cancer.
Prostates and bladders of the animals were examined by light
and electron microscopy. At 60 days after irradiation, no gross
pathology was observed (data not shown). However, ultrastructural damage was clearly observed by electron microscopy (Fig. 1C). Mitochondrial damage was most pronounced
and this was morphometrically analyzed. The number of
damaged mitochondria in prostate and bladder was proportional to radiation exposure. Pretreatment with DMAPT signiÔ¨Åcantly reduced the number of damaged mitochondria in
both organs compared with the group without DMAPT treatment (Fig. 1C and D). These results indicate that DMAPT, the
water-soluble prodrug of parthenolide, is a promising agent for
selectively enhancing the sensitivity of prostate cancer cells to
radiation while protecting normal tissues from damage caused
by radiation.
Parthenolide differentially modulates cellular ROS levels
in cancer and normal cells
To determine the effect of parthenolide on redox homeostasis in cancer and normal cells, the levels of superoxide and
total ROS after parthenolide treatment were measured using
Ô¨Çow cytometry. The mean Ô¨Çuorescence intensity of DHE and
the H2DCFDA:DCFDA ratio were higher in prostate cancer PC3
cells than in normal prostate PZ and PrEC cells, indicating
higher basal levels of superoxide and total ROS, respectively
(Fig. 2A and B). Following parthenolide treatment, DHE and
DCF levels increased further in PC3 cells but declined slightly in
both types of noncancerous cells. Combining PEG-SOD with
parthenolide treatment restored the basal level of DHE Ô¨Çuorescence. As positive controls, addition of equivalent concentrations of the ROS-stimulating agents antimycin (Fig. 2A) and
phorbol-12-myristate-13-acetate (PMA; Fig. 2B) caused high
levels of ROS in all the tested cell lines.
The levels of antioxidant proteins were also quantiÔ¨Åed
(Fig. 2C). Parthenolide altered the protein level of the antioxidant enzymes, in particular mitochondria-localized antioxidant enzymes. MnSOD and glutathione peroxidase (GpX)
were signiÔ¨Åcantly reduced in all 3 parthenolide-treated prostate cancer cell lines. Intriguingly, parthenolide had the

Cancer Research

Downloaded from cancerres.aacrjournals.org on September 2, 2017. ¬© 2013 American Association for Cancer Research.

Published OnlineFirst May 14, 2013; DOI: 10.1158/0008-5472.CAN-12-4297

Keap1, a Central Regulator of Cellular Redox Signaling

opposite effect in the 3 normal prostate cell lines. However,
neither cancer nor normal cells showed any obvious changes
after parthenolide treatment for the major cytosolic superoxide removal protein, copper, and zinc-containing SOD (CuZnSOD). This observation was conÔ¨Årmed by quantiÔ¨Åcation of the
corresponding enzyme activity (Fig. 2D). These results suggest
that parthenolide-mediated alteration of cellular redox status
is mediated, at least in part, by changing the activities of
antioxidant enzymes in mitochondria.
To probe whether altering cellular redox status is associated
with a change in mitochondrial respiration, the OCR in the
parthenolide-treated cells was measured using a Seahorse
Bioscience FX OxygenFlux Analyzer. The basal and maximal
OCR in normal cells was higher than in cancer cells (Fig. 2E).
Importantly, parthenolide was able to increase the OCR and
reserve capacity in PZ cells, whereas parthenolide had no effect
on PC3 OCR. Finally, the cytotoxicity of parthenolide was

A

tested in all the cell lines using an MTT assay, which requires
active mitochondria. As shown in Fig. 2F, parthenolide was
toxic to all the cancer cells but not to the normal cell lines.
Taken together, these results suggest that changes in cellular
redox status and mitochondrial function may be a cause for the
differential biologic effects of parthenolide on cancer and
normal cells.
Keap1 is susceptible to parthenolide-mediated redox
modiÔ¨Åcation
Keap1, a redox-sensitive protein, has been reported to play
an important role in cell survival under oxidative stress (29). To
investigate whether parthenolide modiÔ¨Åes Keap1 function, a
Keap1 antibody linked to biotin was used to immunoprecipitate redox-modiÔ¨Åed Keap1 protein and the presence of oxidized (-S-S-) and reduced (-SH) cysteine residues was detected
using a secondary antibody linked to streptavidin. In the 3

C

3,000

Untreated

5 x 3 Gy

DMAPT + 5 x 3 Gy

DMAPT

Tumor volume (mm3)

2,500

a

1 Gy

b

1 Gy + DMAPT
2,000

2 Gy

Prostate

2 Gy + DMAPT
1,500

12,000X

12,000X

1,000

c

d

500

Bladder

0
0

2

4

6

8 11 14 17 20 24 28 32 36

Days after treatment

8,000X
P < 0.05

B

D
100

P < 0.01

50

P < 0.05

40
30
20
10

D

5 x 3Gy

DMAPT/5 x 3Gy

*P < 0.05

80

*
60

*

40

20

0
Prostate

Bladder

2

G

y

+

+
G
y
1

M
AP
T

y
G

D

2

y

M
AP
T

G
1

M
AP
T
D

U

nt

re
at

ed

0

% Damaged mitochondria / total
mitochondria

Days when tumor volume
reaches to 2,000 (mm3)

70
60

8,000X

Figure 1. The effect of parthenolide on radiosensitivities of prostate cancer and normal cells. A, prostate cancer PC3 cells were injected into the Ô¨Çanks of nude
male mice. The resulting tumors were treated with DMAPT and IR. Tumor volume was measured and tumor growth was calculated. B, time needed for
3
tumor growth to reach 2,000 mm volume after treatment was calculated and plotted. C, mice without cancer were treated with radiation alone (5  3 Gy) and
DMAPT (10 mg/kg) with radiation. Prostate and bladder tissues were removed for pathologic analysis using electron microscopy. Arrows indicate normal
mitochondria and asterisks indicate mitochondria with myelin Ô¨Ågures. M, normal mitochondria; Ly, lysosome; and V, mitochondria with vacuoles. D,
quantiÔ¨Åcation of mitochondrial damage in mice prostate and bladder tissues.

www.aacrjournals.org

Cancer Res; 73(14) July 15, 2013

Downloaded from cancerres.aacrjournals.org on September 2, 2017. ¬© 2013 American Association for Cancer Research.

4409

Published OnlineFirst May 14, 2013; DOI: 10.1158/0008-5472.CAN-12-4297

Xu et al.

A

D 200
DHE assay

PZ

*

PrEC

#

1,500

*

$

1,000

500

Enzyme activity (units/min/mg)

Mean fluorescence intensity

2,000

PC3

0

PC3/PN

160

PZ/DMSO

140

PZ/PN

120

PrEC/DMSO

100

PrEC/PN

80

*

60

*

*

40

*

0

DCF assay
PC3

120

# $

80
60
40
20
0

PN (5 Œºmol/L) PMA (5 Œºmol/L)

DMSO

Catalase

GpX

P < 0.01

300

PrEC

OCR (pMoles/min/mgprotein)

H2DCFDA/DCFDA

*

CuZnSOD

E

PZ

*

100

*

*

MnSOD

B

PC3/DMSO

180

20

PN (5 Œºmol/L) PN+PEG-SOD Antimycin
(5 Œºmol/L)
(50 Œº/mL)

DMSO

*P < 0.05

250
200

PZ
PZ+PN
PC3
PC3+PN

P < 0.01

150

NS

P < 0.05

P < 0.01

NS

100

NS

NS
50
0

+

+ -

+ -

+ -

+

R
W
PE
-1

EC
Pr

PZ

-1
45
LN
C
aP

-

-

F

ATP-linked

Maximal OCR

Reserve
capacity

120
PC3

100

+
MnSOD
GpX
CuZnSOD

Cell survival (%)

PN (5 Œºmol/L) -

Basal

Normal cells

D
U

PC
3

C

Cancer cells

DU-145
LNCaP

80

PZ
RWPE-1

60

PrEC

40
20

Catalase
0
Œ≤-Actin

0

1

2

3

4

5

PN (Œºmol/L)

Figure 2. The effect of parthenolide on redox homeostasis in prostate cancer and normal cells. A‚ÄìB, cells were treated with parthenolide and then labeled
with DHE or DCF. The mean Ô¨Çuorescence intensity of DHE (A) and the ratio of H2DCFDA to DCFDA (B) were determined using Ô¨Çow cytometry. Concentrations
of cellular superoxide and total ROS were estimated by quantiÔ¨Åcation of Ô¨Çuorescence intensity. Antimycin and PMA were used as positive controls for
generation of ROS. PEG-SOD was used as a control to remove superoxide generated by DHE. PN, parthenolide.  , #, $ indicate the signiÔ¨Åcances of
treatments compared to DMSO untreated control in PC3 ( ), PZ (#), and PrEC ($) cells. C, the levels of antioxidant proteins were quantiÔ¨Åed by Western blots.
D, the activities of the corresponding enzymes were measured. E, quantiÔ¨Åcation of the basal oxygen consumption, ATP-linked oxygen consumption, the
maximal OCR after the addition of FCCP, and the reserve capacity of the cells. NS, not signiÔ¨Åcant. F, three cancer cell lines and 3 noncancer cell lines were
treated with parthenolide (PN) at the indicated concentrations. Cell survival fraction was determined by MTT assay.

normal cell lines, parthenolide increased the oxidized form of
Keap1 but decreased the reduced form of Keap1 (Fig. 3A).
Interestingly, the results from the 3 cancer cell lines seemed to
be completely opposite to results observed in normal cells
treated with parthenolide: the level of the oxidized form was
decreased, but the level of the reduced form was increased

4410

Cancer Res; 73(14) July 15, 2013

(Fig. 3B). To verify that the observed increase in reduced Keap1
also occurred in vivo, mouse xenograft tumor tissues with and
without DMAPT treatment were also used for determination of
Keap1 redox status. Consistent with data obtained from cultured tumor cells treated with parthenolide, the in vivo results
show that parthenolide decreased the oxidized form of Keap1

Cancer Research

Downloaded from cancerres.aacrjournals.org on September 2, 2017. ¬© 2013 American Association for Cancer Research.

Published OnlineFirst May 14, 2013; DOI: 10.1158/0008-5472.CAN-12-4297

Keap1, a Central Regulator of Cellular Redox Signaling

A

PZ-HPV-7
-S-S-

PN

‚àí

RWPE-1

-SH

+

‚àí

-S-S-

+

PN

‚àí

-SH

+

‚àí

C

PrEC
-S-S-

+

PN

-SH

-S-S-

-SH

‚àí

+

‚àí

DMAPT

+

‚àí

+

‚àí

+

Keap1
Keap1

IgG

IgG

IgG

-SH

+

‚àí

-S-S-

+

PN

‚àí

+

-SH

‚àí

D

LNCaP
-S-S-

+

PN

‚àí

-SH

+

‚àí

* P < 0.05

+

DMSO
DMAPT

M
SO

140

Keap1

Keap1

Fold change (%)

D

120
Keap1

MnSOD

100
80

T

‚àí

DU-145

IgG

M
AP

PC-3
-S-S-

PN

Keap1

D

B

Keap1

*

GPX

*

60

Catalase

40

CuZnSOD

20

Œ≤-Actin

0
IgG

IgG

IgG

MnSOD

GpX

CuZnSOD Catalase

Figure 3. Keap1 redox modiÔ¨Åcation by parthenolide. A and B, 3 normal cell lines (A) and 3 prostate cancer cell lines (B) were treated with saline or
parthenolide (PN). Keap1 was immunoprecipitated with its antibody and SH- and S-S moieties of Keap1 were shown by ECL detection. C, tumor tissues were
homogenized and incubated with MPB. Reduced (SH-) and oxidized (S-S) forms of Keap1 in the tissues were detected. D, tumor tissues were homogenized
and antioxidant proteins were quantiÔ¨Åed by Western blots. Right, representative blots. Left, the average of multiple blots.

but increased the reduced form of Keap1 in the tumors (Fig.
3C). Changes in antioxidant proteins in mouse xenograft tumor
tissues treated with DMAPT are also consistent with the result
obtained from in vitro studies (Fig. 3D), indicating that parthenolide decreases the level of mitochondrial antioxidant proteins in prostate tumors.
Oxidization of Keap1 leads to activation of the Nrf2
prosurvival pathway in normal cells
Activation of the Nrf2 signaling pathway through dissociation with Keap1 resulting in Nrf2 nuclear translocation is
considered to be a primary prosurvival pathway in response
to oxidative stress (30, 37). To examine whether parthenolide
changes Nrf2 nuclear translocation, the levels of Nrf2 in nuclei
were measured. As shown in Fig. 4A, the nuclear levels of Nrf2
were increased in the 3 normal cell lines treated with parthenolide, but no changes were observed in the 3 cancer cell lines.
To examine whether activation of the Nrf2 pathway is a major
mechanism by which parthenolide protects normal cells
against radiation injury, Keap1 and Nrf2 were silenced in PZ
cells by transfecting their siRNA (Fig. 4B, left). Cell survival
decreased when Nrf2 was silent. IR signiÔ¨Åcantly reduced cell
survival but the cell survival was restored when Keap1 was
silenced (Fig. 4B, right panel). These results suggest that

www.aacrjournals.org

oxidation of Keap1 and subsequent activation of Nrf2 by
parthenolide is essential for normal cell survival after radiation
treatment.
Thioredoxin is necessary for parthenolide-mediated
reduction of Keap1 in cancer cells
TrX is highly expressed in cancer cells and stimulates cell
growth. We previously reported that parthenolide decreases
the reduced form of TrX but increases the oxidized form of TrX
in prostate cancer cells (25). In the present study, we verify that
TrX was expressed at a high level in all 3 cancer cell lines,
whereas a low level was observed in the 3 noncancer cell lines
(Fig. 5A). Immunoprecipitation of Keap1 protein from PC3 cell
extracts using a TrX antibody suggests an interaction between
Keap1 and TrX that is increased by parthenolide (Fig. 5B). To
detect whether the parthenolide-inÔ¨Çuenced reduction of
Keap1 in cancer cells is dependent on TrX, we selectively
silenced TrX by transfecting its siRNA before parthenolide
treatment (Fig. 5C, left). As expected, the reduced form of
Keap1 was decreased, but the oxidized form of Keap1 was
increased when TrX was silent (Fig. 5C, middle and right). The
results suggest that TrX is interacting with Keap1 to keep
Keap1 in a reduced state in parthenolide-treated cells. To
further conÔ¨Årm that the function of Keap1 leads to cell death

Cancer Res; 73(14) July 15, 2013

Downloaded from cancerres.aacrjournals.org on September 2, 2017. ¬© 2013 American Association for Cancer Research.

4411

Published OnlineFirst May 14, 2013; DOI: 10.1158/0008-5472.CAN-12-4297

Xu et al.

A

PC3

‚àí

PN (5 Œºmol/L)

+

DU-145

‚àí

LNCaP

+ ‚àí

+ ‚àí

PZ

PrEC

+

‚àí

+

RWPE-1

‚àí

+
Nrf2

PCNA

B

+

+

N
rf2

si
R
N
A

1
ap
Ke

‚àí

‚àí

+
Keap1
Nrf2
Œ≤-Actin

Cell survival (%)

PN (5 Œºmol/L) ‚àí

si

C
trl
si
R
N
A

R
N
A

P < 0.01
P < 0.01
140

Ctrl siRNA

120

Keap1 siRNA
Nrf2 siRNA

100
80
60
40
20

Figure 4. Activation of Keap1-Nrf2
pathway by parthenolide in normal
cells. A, parthenolide (PN)
increases nuclear levels of Nrf2 in
normal cells but not in cancer cells.
Nuclear proteins extracted from
the parthenolide-treated cell lines
were immunoblotted to quantify
nuclear levels of Nrf2 using PCNA
as loading control. B, the effect of
Keap1 and Nrf2 in normal cells. PZ
cells were transfected with siRNAs
to knock down Keap1 or Nrf2,
respectively. After treatment with
parthenolide and IR, the cell
survival fraction was quantiÔ¨Åed
using Trypan blue exclusion assay
(right) and the knocked down
Keap1 and Nrf2 were conÔ¨Årmed by
Western blots (left).

0
Untreated

in parthenolide-treated cancer cells, a Keap1 expression construct was transfected into PC3 cells, followed by parthenolide
and IR treatments. Overexpression of Keap1 resulted in
increases in cell death in both treated and untreated cells (Fig.
5D, top). The levels of mitochondrial phosphoglycerate mutase
5 (PGAM5), a protein serine/threonine phosphatase that interacts with Bcl-xL in the mitochondrial membrane (38), and BclxLwere clearly decreased in the Keap1-transfected cells, but no
changes were observed in Nrf2, Ikka, and IkBa (Fig. 5D,
bottom). These results suggest that the parthenolide-increased
reduced form of Keap1 facilitates Keap1-mediated ubiquitin/
proteasome-dependent degradation of PGAM5 and Bcl-xL,
which is an established mechanism for parthenolide-mediated
cell death in cancer cells.
Keap1 triggers PGAM5-mediated Bcl-xL ubiquitin
degradation in parthenolide-treated cancer cells
To further investigate the mechanism by which parthenolide
enhances the radiosensitivity of prostate cancer cells, we
determined the interactions between Keap1, PGAM5, and
Bcl-xL. The results show that a reduced form of Keap1, which
is increased in parthenolide-treated PC3 cells, enhanced interaction between Keap1 and PGAM5, as detected by immunoprecipitation using a PGAM5 antibody (Fig. 6A). Bcl-xL, a
prosurvival mitochondrial protein, was also increased in the
pulled down complex (Fig. 6A). Interestingly, the proteins that
are associated with Keap1 were decreased in whole-cell
extracts (Fig. 6B). A time course of parthenolide treatment
shows that PGAM5 and Bcl-xL proteins were slightly increased
at 12 hours but decreased at 24 and 48 hours after treatment
(Fig. 6C). Proteins in different cellular fractions were also
quantiÔ¨Åed (Fig. 6D). The mitochondria-associated proteins
PGAM5 and Bcl-xL were reduced by the parthenolide treatment, but no change was observed in Hsp75, a control for
mitochondrial protein. Parthenolide had no major effect on the

4412

Cancer Res; 73(14) July 15, 2013

6 Gy

PN 5 Œºmol/L PN + 6Gy

levels of Nrf2 and Ikka in treated cells. These results suggest
that parthenolide enhances Keap1-mediated ubiquitin/proteasome-dependent degradation of PGAM5 and Bcl-xL (39).
In addition, parthenolide increased the level of mitochondriaassociated autophagic protein LC3B, suggesting that parthenolide may enhance the radiation sensitivity of prostate cancer
cells partially through triggering the autophagy pathway.
Because Keap1 interacts with PGAM5/Bcl-xL/Nrf2, we
decided to determine the effect of PGAM5/Bcl-xL/Nrf2 in
mediating parthenolide's effect on cancer cells. PGAM5, BclxL, and Nrf2 were silenced using their siRNAs, followed by
parthenolide treatment (Fig. 6E, bottom). The cell survival
fraction was decreased when PGAM5 or Bcl-xL was silent,
which is similar to the effect of parthenolide (Fig. 6E, top). No
signiÔ¨Åcant additive effects were observed when parthenolide
was combined with PGAM5 or Bcl-xL siRNA. In contrast, a
signiÔ¨Åcant effect was observed when Nrf2 was silent. These
results suggest that Keap1-mediated PGAM5/Bcl-xL degradation, but not Nrf2 degradation, is important for parthenolideinduced cancer cell death.
To further determine whether the function of Bcl-xL plays a
major role in protecting cancer cells against parthenolideinduced cell death, a plasmid carrying Bcl-xL cDNA was
transfected into PC3 cells followed by parthenolide treatment
(Fig. 6F, bottom). The results show that expression of Bcl-xL
efÔ¨Åciently protects cells from cytotoxicity caused by parthenolide (Fig. 6F, top). Taken together, these results suggest that
parthenolide enhances the radiosensitivity of prostate cancer
cells, in part, by triggering ubiquitin/proteasome-based degradation of Bcl-xL.
In summary, parthenolide provides radiosensitization in
prostate cancer cells but radioprotection in normal cells, and
the observed differential effects are mediated, in part, by redox
modiÔ¨Åcation of Keap1, i.e., reducing Keap1 in cancer cells
but oxidizing Keap1 in normal cells. The distinct redox

Cancer Research

Downloaded from cancerres.aacrjournals.org on September 2, 2017. ¬© 2013 American Association for Cancer Research.

Published OnlineFirst May 14, 2013; DOI: 10.1158/0008-5472.CAN-12-4297

Keap1, a Central Regulator of Cellular Redox Signaling

A

IP

B

PN (5 Œºmol/L)

PC3
PN (5 Œºmol/L)

‚àí

DU145

+

‚àí

LNCaP

+

‚àí

+

PZ

‚àí

PrEC

+ ‚àí

TrX

‚àí

IgG

+

+

RWPE-1

‚àí

+

+
Keap1

TrX
Œ≤-Actin

TrX
siRNA ctrl siRNA TrX

C

‚àí

PN (5 Œºmol/L)

+

‚àí

D

+
Cell survival (%)

Keap1
TrX
Œ≤-Actin

-S-S-

-SH

100
80

*
*

60
40

*

Untreated

+

*

20
0

siRNA ctrl siRNA TrX

‚àí

Vector
Keap1

* P < 0.05

120

‚àí

+

6Gy

PN (5 Œºmol/L) PN+6Gy

siRNA ctrl siRNA TrX
PN (5 Œºmol/L)

‚àí

+

‚àí

Vector

+

‚àí

+

Keap1

‚àí

+

PN (5 Œºmol/L)
Nrf2

Keap1

Keap1
PGAM5
Bcl-xL
IkkŒ±

IgG

IkBŒ±
Œ≤-Actin

Figure 5. TrX-dependent Keap1 reduction by parthenolide in prostate cancer cells. A, the levels of TrX in normal and cancer cells before and after treatment
with parthenolide (PN) were detected by Western blots. B, after the indicated treatment, Keap1 was immunoprecipitated using a TrX antibody. C, PC3
cells were transfected with TrX siRNA before the indicated treatment (top). SH- and S-S bands in Keap1 protein were detected as described in Fig. 3 (bottom).
D, a Keap1 cDNA construct was transfected into PC3 cells. The levels of related proteins were detected by Western blots (bottom). The effect of Keap1 on
radiosensitivity was analyzed using a Trypan blue exclusion assay (top).

modiÔ¨Åcation of Keap1 initiates different signaling pathways
that affect mitochondrial function, leading to cell survival or
cell injury in response to radiation, as illustrated in Fig. 7.

Discussion
The majority of anticancer therapies fail because cancers
develop phenotypes that are treatment resistant and because
treatments cause unwanted and/or detrimental side effects to
normal cells or to untargeted tissues. While conventional
adjuvant therapies improve tumor response to radiotherapy,
they generally cause additional damage to normal tissues.
Thus, the focus of the present study is to identify adjuvant
therapeutics that can reduce the side effects of radiotherapy.
Our study provides a proof-of-concept for improving the
efÔ¨Åcacy of radiotherapy while protecting against injury to

www.aacrjournals.org

normal tissues. It has been shown that parthenolide, the
anti-inÔ¨Çammatory phytochemical, is able to suppress tumor
growth in many organs (22‚Äì25). In addition, parthenolide
seems to synergically enhance chemotherapeutic efÔ¨Åciency
when it is combined with taxol or cisplatin to treat lung and
gastric cancer cells (23, 40). Parthenolide also sensitizes radioresistant osteosarcoma cells to radiotherapy (41). Here, we
show that DMAPT, a parthenolide prodrug, sensitized prostate
cancer cells to radiotherapy in vivo and protected normal
prostate and bladder against radiation-induced tissue injury.
These results extend our previous survival studies in prostate
cancer cell lines and normal prostate epithelial cells.
ROS, as products of cell metabolism, play a dual role in
tumorigenesis and tumor suppression. The "two-faced" character of ROS has emerged as a potential source for discovering
anticancer drugs. Redox homeostasis is frequently deregulated

Cancer Res; 73(14) July 15, 2013

Downloaded from cancerres.aacrjournals.org on September 2, 2017. ¬© 2013 American Association for Cancer Research.

4413

Published OnlineFirst May 14, 2013; DOI: 10.1158/0008-5472.CAN-12-4297

Xu et al.

A

PN (5 Œºmol/L)

‚àí

PN (5 Œºmol/L) +

‚àí

+

ch

ol
C
yt

M
ito

os

le
W
ho

IP: PGAM5
IgG

on

dr
ia

D
‚àí

‚àí

+

+

+

Keap1
Keap1

E

Nrf2

PGAM5

P < 0.01

PGAM5

Bcl-xL

Bcl-xL

IgG

LC3B1
LC3B2

DMSO
PN

P < 0.01

120

P < 0.01

B

IkkŒ±
+
Hsp75

Keap1

Œ≤-Actin

60
40
20

F

0

PGAM5

DMSO

P < 0.01

Œ≤-Actin

C

12 h

24 h

+

‚àí

+

‚àí

+

A
si
L
l-x

Bc

+

A

N
R

R
5

‚àí

‚àí

+ ‚àí

+
Nrf 2

20

48 h
‚àí

si

A
N

PN (5 Œºmol/L)

40

PGAM5

0
PN (5 Œºmol/L) ‚àí

AM

R
si

60

PG

trl

80

C

Cell survival (%)

LC3B2

Nrf2 siRNA

N

100

Bcl-xL siRNA

A

120

LC3B1

PGAM5 siRNA

N

Bcl-xL

Ctrl siRNA

PN
si
R

Nrf2

80

rf2

‚àí

P < 0.01

N

PN (5 Œºmol/L)

Cell survival (%)

100

Vector

+

Bcl-xL

Bcl-xL

PN (5 Œºmol/L) ‚àí

Œ≤-Actin

l-x
Bc

ct
BcL-xL

Ve

PGAM5

Œ≤-Actin

L

or

Keap1

+ ‚àí

+
Bcl-xL
Œ≤-Actin

Figure 6. Degradation of PGAM5-Bcl-xL caused by parthenolide-mediated reduction of Keap1 in prostate cancer cells. A, PC3 cells were treated with
parthenolide (PN). Keap1 and Bcl-xL were immunoprecipitated using a PGAM5 antibody. B, the total levels of Nrf2, PGAM5, and Bcl-xL were
quantiÔ¨Åed by Western blots. C, the levels of mitochondria- associated proteins after parthenolide treatments. D, proteins in various cellular fractions
were identiÔ¨Åed with antibody speciÔ¨Åc for each protein. E, PC3 cells were transfected with siRNA to knockdown PGAM5, Bcl-xL, and Nrf2, respectively
(bottom). Cell survival fraction was quantiÔ¨Åed by Trypan blue exclusion assay (top). F, a Bcl-xL expression construct was transfected into PC3 cells and the
expression of Bcl-xL was monitored by Western blots (bottom). Cell survival fraction was quantiÔ¨Åed by Trypan blue exclusion assay (top).

in cancers, as it is constantly exposed to high levels of ROS
compared with normal counterparts. Our data show that
constitutively elevated levels of oxidative stress in cancer cells
represent a speciÔ¨Åc vulnerability that can be selectively targeted by direct- or indirect-acting prooxidants and antioxidants or redox modulators. Theoretically, the differential redox
status of cancer cells compared with normal cells should
provide a therapeutic window for selective redox intervention
via additional increases in ROS. In this context, normal and
cancer cells should respond differently to the same level of
prooxidant action generated either by direct production of
oxidative species or by modulation of speciÔ¨Åc cellular targets
involved in redox regulation. In this study, we show that
parthenolide serves as a prooxidant and displays a selective
redox modiÔ¨Åcation capability that differentially modulates
cellular redox signals and targets. The Michael acceptor reacts
with a thiol group of target proteins through covalent adduc-

4414

Cancer Res; 73(14) July 15, 2013

tion (21). Parthenolide contains electrophilic a-methyleneg-lactone, a bisfunctional Michael acceptor, and displays a
potential for bifunctional target alkylation and crosslinking.
The present study shows the inverse effects of parthenolide on
redox modiÔ¨Åcation in cancer cells compared with normal cells.
Remarkably, observations of the cytotoxic and cytoprotective
effects of parthenolide are consistent with its action in the
modulation of ROS levels in both cancer and normal cells.
Alteration of cellular ROS by parthenolide is attributed to
functionally up- or downregulating antioxidant enzymes in
mitochondria, which consequently regulates mitochondrial
respiration. Parthenolide is able to selectively reduce the
activity of several enzymes involved in oxidative stress removal
in cancer cells, which in turn can cause ROS levels to rise above
the threshold for cell death. This Ô¨Ånding predicts that antioxidant proteins and mitochondria are feasible therapeutic
targets.

Cancer Research

Downloaded from cancerres.aacrjournals.org on September 2, 2017. ¬© 2013 American Association for Cancer Research.

Published OnlineFirst May 14, 2013; DOI: 10.1158/0008-5472.CAN-12-4297

Keap1, a Central Regulator of Cellular Redox Signaling

Parthenolide

Radiation
Cancer cells

Normal cells
Figure 7. A proposed mechanistic
model for parthenolide-mediated
inverse therapeutic effects on
radiosensitivity of prostate cancer
and radioresistance of normal
cells. Parthenolide sensitizes
cancer cells to radiation, in part, by
maintaining Keap1 in a reduced
state and enhancing its interaction
with PGAM5 and Bcl-xL, resulting
in degradation of Bcl-xL in
mitochondria. In contrast,
parthenolide protects normal cells
against radiation via oxidation of
Keap1 and release of the Nrf2
transcription factor for activation of
mitochondrial antioxidant
enzymes.

Cytosol
red

red
Cell defense

ox
Protection

Degradation
Nucleus

Cell death
Antioxidants

It has been reported that parthenolide is a potent inhibitor of
NF-kB, which is a ROS-responsive transcriptional factor
involved in both tumor progression and tumor resistance to
treatment through upregulation of antiapoptotic genes, such
as Bcl-2, Bcl-xL, survivin, and XIAP (42). We previously showed
that NADPH oxidase-mediated inactivation of the Foxo 3
signaling pathway is involved in the parthenolide-enhanced
radiosensitivity of prostate cancer (25). However, previous
studies did not explain how parthenolide exerts such an
opposing effect in tumor and normal cells. The present study
identiÔ¨Åes Keap1 as a redox signaling sensor that plays a pivotal
role in the differential regulation of the downstream signaling
targets in response to radiation-mediated cytotoxicity in prostate cancer and normal cells. Keap1, an adaptor protein for
ubiquitin-based processing by the CUL3/RBX1-dependent E3
ubiquitin ligase complex, functions as a sensor for thiol-reactive redox modiÔ¨Åcation (43). The present study shows that
stabilization of Nrf2 by oxidation of Keap1 serves as a major
mechanism by which parthenolide protects normal tissues
against radiotoxicity through upregulation of antioxidant
enzymes in mitochondria. However, Nrf2 transcriptional activation did not play a major role in parthenolide-treated
prostate cancer cells. Thus, it is interesting to note that unlike
traditional chemotherapeutic agents, parthenolide is unable to
enhance resistance of prostate cancer to radiation treatment
by stimulating Nrf2 target genes.
In addition to regulating the Nrf2 signaling pathway, Keap1
is able to bind other proteins such as p62 and PGAM5 (44).
Interaction between Keap1 and p62 facilitates release of Nrf2
from the complex, which is considered to be a noncanonical
cysteine-independent mechanism for the autophagy deÔ¨Åcien-

www.aacrjournals.org

cy‚Äìactivated Nrf2 pathway (45). The N-terminus of PGAM5
interacts with the Kelch domain of Keap1 and its C-terminus
binds to Bcl-xL. Keap1-dependent ubiquitination results in
proteasome-dependent degradation of PGAM5 and Bcl-xL
(38). Bcl-xL, an important member of the Bcl-2 family, is a
potent antiapoptotic factor that plays a crucial role in cell
survival by maintaining the electrochemical and osmotic
homeostasis of mitochondria (46). The present study shows
that parthenolide increases the level of reduced Keap1 and
consequently induces Keap1-dependent degradation of
PGAM5 and Bcl-xL in cancer cells, suggesting that formation
of the Keap1-PGAM5-Bcl-xL complex is a mechanism underlying the effect of parthenolide on radiosensitization of prostate cancer cells.
Although a high rate of aerobic glycolysis in tumors, known
as the Warburg effect, has been observed in various types of
cancer, cancers have functional mitochondria, and mitochondrial respiration is necessary for cancer cell proliferation (47).
Cancer cells depend on a hyperactive metabolism to fuel their
rapid growth and also on antioxidative enzymes to quench
potentially toxic ROS generated by such a high metabolic
demand (48). Our results show that parthenolide not only
suppresses MnSOD and GpX, 2 major antioxidant enzymes in
mitochondria, but also activates Bcl-xL degradation in cancer
cells, which suggests that mitochondria are a feasible target for
anticancer treatment. The present study also shows that
parthenolide may maintain normal cell survival through induction of MnSOD and GpX activity. Thus, a more efÔ¨Åcient and safe
therapy may involve modiÔ¨Åcation of cellular redox signaling by
alteration of the antioxidant response coupled to selective
degradation of prosurvival members of the Bcl2 family in

Cancer Res; 73(14) July 15, 2013

Downloaded from cancerres.aacrjournals.org on September 2, 2017. ¬© 2013 American Association for Cancer Research.

4415

Published OnlineFirst May 14, 2013; DOI: 10.1158/0008-5472.CAN-12-4297

Xu et al.

cancer cells, as conventional anticancer therapy mainly causes
cell growth arrest or cell death by raising cellular ROS, which
oxidizes and damages DNA, proteins, and lipids. Optimizing
prototype redox chemotherapeutics from natural sources provides an exciting opportunity to further develop even better
candidates to enhance therapeutic efÔ¨Åcacy with less off-target
toxicity.

Writing, review, and/or revision of the manuscript: Y. Xu, S. Miriyala, P.A.
Crooks, D.K. St. Clair, W.H. St. Clair
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): Y. Xu, T. Noel
Study supervision: Y. Xu, D.K. St. Clair, W.H. St. Clair

Acknowledgments
The authors thank Yulan Sun, a previous graduate student, who initiated the
work.

Disclosure of Potential ConÔ¨Çicts of Interest
No potential conÔ¨Çicts of interest were disclosed.

Authors' Contributions
Conception and design: Y. Xu, P.A. Crooks, D.K. St. Clair, W.H. St. Clair
Development of methodology: Y. Xu, F. Fang, S. Miriyala
Acquisition of data (provided animals, acquired and managed patients,
provided facilities, etc.): Y. Xu, F. Fang, L. Chaiswing, A.K. Holley, Y. Zhao, K.K.
Kiningham, D.K. St. Clair, W.H. St. Clair
Analysis and interpretation of data (e.g., statistical analysis, biostatistics,
computational analysis): Y. Xu, F. Fang, S. Miriyala, P.A. Crooks, T.D. Oberley,
D.K. St. Clair, W.H. St. Clair

Grant Support
This work was supported by NIH grants CA49797, CA115801, and CA143428
(to D.K. St. Clair and William St. Clair). Additional support was provided by the
Edward P. Evans Foundation and by the resources and facilities of the William
S. Middleton Veterans Administration Hospital (Madison, WI).
The costs of publication of this article were defrayed in part by the payment
of page charges. This article must therefore be hereby marked advertisement
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received November 27, 2012; revised March 18, 2013; accepted April 5, 2013;
published OnlineFirst May 14, 2013.

References
1.

2.
3.
4.
5.

6.

7.
8.

9.

10.
11.
12.

13.
14.

15.

16.

4416

Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, et al. Mitogenic
signaling mediated by oxidants in Ras-transformed Ô¨Åbroblasts. Science 1997;275:1649‚Äì52.
Rhee SG. Cell signaling. H2O2, a necessary evil for cell signaling.
Science 2006;312:1882‚Äì83.
Pelicano H, Carney D, Huang P. ROS stress in cancer cells and
therapeutic implications. Drug Resist Updat 2004;7:97‚Äì110.
Tew KD, Townsend DM. Redox platforms in cancer drug discovery and
development. Curr Opin Chem Biol 2011;15:156‚Äì61.
D'Autreaux B, Toledano MB. ROS as signalling molecules: Mechanisms that generate speciÔ¨Åcity in ROS homeostasis. Nat Rev Mol Cell
Biol 2007;8:813‚Äì24.
Xia C, Meng Q, Liu LZ, Rojanasakul Y, Rojanasakul Y, Wang XR, et al.
Reactive oxygen species regulate angiogenesis and tumor growth
through vascular endothelial growth factor. Cancer Res 2007;67:
10823‚Äì30.
‚Ç¨ ge W. Free radicals in the physiological control of cell function.
Dro
Physiol Rev 2002;82:47‚Äì95.
Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free
radicals and antioxidants in normal physiological functions and human
disease. Int J Biochem Cell Biol 2007;39:44‚Äì84.
Cabello CM, Bair WB III, Wondrak GT. Experimental therapeutics:
targeting the redox Achilles heel of cancer. Curr Opin Investig Drugs
2007;8:1022‚Äì37.
Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P. Redox
regulation of cell survival. Antioxid Redox Signal 2008;10:1343‚Äì74.
Wang J, Yi J. Cancer cell killing via ROS to increase or decrease, that is
the question. Cancer Biol Ther 2008;7:1875‚Äì84.
Spyratou E, Makropoulou M, Mourelatou EA, Demetzos C. Biophotonic techniques for manipulation and characterization of drug
delivery nanosystems in cancer therapy. Cancer Lett 2012;327:
111‚Äì22.
Oberley L, Oberley TD. Role of antioxidant enzymes in cell immortalization and transformation. Mol Cell Biochem 1988;84:147‚Äì53.
Zhao Y, Chaiswing L, Oberley TD, Batinic-Haberle I, St Clair W, Epstein
CJ, et al. A mechanism-based antioxidant approach for the reduction
of skin carcinogenesis. Cancer Res 2005;65:1401‚Äì5.
Dhar SK, Tangpong J, Chaiswing L, Oberley TD, St Clair DK. Manganese superoxide dismutase is a p53-regulated gene that switches
cancers between early and advanced stages. Cancer Res 2011;71:
6684‚Äì95.
Josson S, Xu Y, Fang F, Dhar SK, St Clair DK, St Clair WH. RelB
regulates manganese superoxide dismutase gene and resistance to
ionizing radiation of prostate cancer cells. Oncogene 2006;25:
1554‚Äì59.

Cancer Res; 73(14) July 15, 2013

17. Fan M, Ahmed KM, Coleman MC, Spitz DR, Li JJ. Nuclear factorkappaB and manganese superoxide dismutase mediate adaptive
radioresistance in low-dose irradiated mouse skin epithelial cells.
Cancer Res 2007;67:3220‚Äì28.
18. Homma S, Ishii Y, Morishima Y, Yamadori T, Matsuno Y, Haraguchi N,
et al. Nrf2 enhances cell proliferation and resistance to anticancer
drugs in human lung cancer. Clin Cancer Res 2009;15:3423‚Äì32.
19. Hassane DC, Sen S, Minhajuddin M, Rossi RM, Corbett CA, Balys M,
et al. Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood
2010;116:5983‚Äì90.
20. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, et al. Selective
killing of cancer cells by a small molecule targeting the stress response
to ROS. Nature 2011;475:231‚Äì34.
21. Hwang DR, Wu YS, Chang CW, Chang CW, Lien TW, Chen WC, et al.
Synthesis and anti-viral activity of a series of sesquiterpene lactones
and analogues in the subgenomic HCV replicon system. Bioorg Med
Chem 2006;14:83‚Äì91.
22. Pajak B, Gajkowska B, Orzechowski A. Molecular basis of parthenolide-dependent proapoptotic activity in cancer cells. Folia Histochem
Cytobiol 2008;46:129‚Äì35.
23. Gill KK, Kaddoumi A, Nazzal S. Mixed micelles of PEG(2000)-DSPE
and vitamin-E TPGS for concurrent delivery of paclitaxel and parthenolide: enhanced chemosensitization and antitumor efÔ¨Åcacy against
non-small cell lung cancer (NSCLC) cell lines. Eur J Pharm Sci
2012;46:64‚Äì71.
24. Sun Y, St Clair DK, Fang F, Warren GW, Rangnekar VM, Crooks PA,
et al. The radiosensitization effect of parthenolide in prostate cancer
cells is mediated by nuclear factor-kappaB inhibition and enhanced by
the presence of PTEN. Mol Cancer Ther 2007;9:2477‚Äì86.
25. Sun Y, St Clair DK, Xu Y, Crooks PA, St Clair WH. A NADPH oxidasedependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells. Cancer Res
2010;70:2880‚Äì90.
26. Kishida Y, Yoshikawa H, Myoui A. Parthenolide, a natural inhibitor of
Nuclear Factor-kappaB, inhibits lung colonization of murine osteosarcoma cells. Clin Cancer Res 2007;13:59‚Äì67.
27. Salmeen A, Andersen JN, Myers MP, Meng TC, Hinks JA, Tonks NK,
et al. Redox regulation of protein tyrosine phosphatase 1B involves a
sulphenyl-amide intermediate. Nature 2003;423:769‚Äì73.
28. Rasmussen HH, Hamilton EJ, Liu CC, Figtree GA. Reversible oxidative
modiÔ¨Åcation: implications for cardiovascular physiology and pathophysiology. Trends Cardiovasc Med 2010;20:85‚Äì90.
29. Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD, Kang MI,
Kobayashi A, Yamamoto M, et al. Protection against electrophile and

Cancer Research

Downloaded from cancerres.aacrjournals.org on September 2, 2017. ¬© 2013 American Association for Cancer Research.

Published OnlineFirst May 14, 2013; DOI: 10.1158/0008-5472.CAN-12-4297

Keap1, a Central Regulator of Cellular Redox Signaling

30.

31.

32.

33.

34.

35.

36.

37.

oxidant stress by induction of the phase 2 response: fate of cysteines
of the Keap1 sensor modiÔ¨Åed by inducers. Proc Natl Acad Sci USA
2004;101:2040‚Äì45.
Adam J, Hatipoglu E, O'Flaherty L, Ternette N, Sahgal N, Lockstone H,
et al. Renal cyst formation in Fh1-deÔ¨Åcient mice is independent of the
Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2
signaling. Cancer Cell 2011;20:524‚Äì37.
Neelakantan S, Nasim S, Guzman ML, Jordan CT, Crooks PA. Aminoparthenolides as novel anti-leukemic agents: discovery of the NFkappaB inhibitor, DMAPT (LC-1). Bioorg Med Chem Lett 2009;19:
4346‚Äì9.
Xu Y, Fang F, St Clair DK, Josson S, Sompol P, Spasojevic I, et al.
Suppression of RelB-mediated manganese superoxide dismutase
expression reveals a primary mechanism for radiosensitization effect
of 1alpha, 25-dihydroxyvitamin D(3) in prostate cancer cells. Mol
Cancer Ther 2007;6:2048‚Äì56.
Xu Y, Josson S, Fang F, St Clair DK, Wan XS, Sun Y, et al. RelB
enhances prostate cancer growth: implications for the role of the NFkB alternative pathway in tumorigenicity. Cancer Res 2009;69:
3267‚Äì71.
Slane BG, Aykin-Burns N, Smith BJ, Kalen AL, Goswami PC, Domann
FE, et al. Mutation of succinate dehydrogenase subunit C results in
increased O2. , oxidative stress, and genomic instability. Cancer Res
2006;66:7615‚Äì20.
Bayer EA, Safars M, Wilchek M. Selective labeling of sulfhydryls and
disulÔ¨Ådes on blot transfers using avidin-biotin technology: studies on
puriÔ¨Åed proteins and erythrocyte membranes. Anal Biochem
1987;161:262‚Äì71.
Keller JN, Kindy MS, Holtsberg FW, St Clair DK, Yen HC, Germeyer A,
et al., Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. J Neurosci 1998;18:687‚Äì97.
Wu RP, Hayashi T, Cottam HB, Jin G, Yao S, Wu CC, et al. Nrf2
responses and the therapeutic selectivity of electrophilic compounds

www.aacrjournals.org

38.

39.

40.

41.

42.
43.

44.

45.
46.

47.
48.

in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2010;107:
7479‚Äì84.
Lo SC, Hannink M. PGAM5, a Bcl-xL-interacting protein, is a novel
substrate for the redox-regulated Keap1-dependent ubiquitin ligase
complex. J Biol Chem 2006;281:37893‚Äì903.
Niture SK, Jaiswal AK. Inhibitor of Nrf2 (INrf2 or Keap1) protein
degrades Bcl-xL via phosphoglycerate mutase 5 and controls cellular
apoptosis. J Biol Chem 2011;286:44542‚Äì56.
Sohma I, Fujiwara Y, Sugita Y, Yoshioka A, Shirakawa M, Moon JH,
et al. Parthenolide, an NF-kB inhibitor, suppresses tumor growth and
enhances response to chemotherapy in gastric cancer. Cancer Genomics Proteomics 2011;8:39‚Äì47.
Zuch D, Giang AH, Shapovalov Y, Schwarz E, Rosier R, O'Keefe R,
et al. Targeting radioresistant osteosarcoma cells with parthenolide.
J Cell Biochem 2012;113:1282‚Äì91.
Montero AJ, Jassem J. Cellular redox pathways as a therapeutic target
in the treatment of cancer. Drugs 2011;71:1385‚Äì96.
Sekhar KR, Rachakonda G, Freeman ML. Cysteine-based regulation of
the CUL3 adaptor protein Keap1. Toxicol Appl Pharmacol 2010;244:
21‚Äì26.
Lau A, Wang XJ, Zhao F, Villeneuve NF, Wu T, Jiang T, et al. A
noncanonical mechanism of Nrf2 activation by autophagy deÔ¨Åciency:
direct interaction between Keap1 and p62. Mol Cell Biol 2010;30:
3275‚Äì85.
Rusten TE, Stenmark H. p62, an autophagy hero or culprit? Nat Cell
Biol 2010;12:207‚Äì9.
Vander Heiden MG, Chandel NS, Williamson EK, Schumacker PT,
Thompson CB. Bcl-xL regulates the membrane potential and volume
homeostasis of mitochondria. Cell 1997;91:627‚Äì37.
Weinberg F, Chandel NS. Mitochondrial metabolism and cancer. Ann
NY Acad Sci 2009;1177:66‚Äì73.
Pavlides S, Vera I, Gandara R, Sneddon S, Pestell RG, Mercier I, et al.
Warburg meets autophagy: cancer-associated Ô¨Åbroblasts accelerate
tumor growth and metastasis via oxidative stress, mitophagy, and
aerobic glycolysis. Antioxid Redox Signal 2012;16:1264‚Äì84.

Cancer Res; 73(14) July 15, 2013

Downloaded from cancerres.aacrjournals.org on September 2, 2017. ¬© 2013 American Association for Cancer Research.

4417

Published OnlineFirst May 14, 2013; DOI: 10.1158/0008-5472.CAN-12-4297

KEAP1 Is a Redox Sensitive Target That Arbitrates the Opposing
Radiosensitive Effects of Parthenolide in Normal and Cancer Cells
Yong Xu, Fang Fang, Sumitra Miriyala, et al.
Cancer Res 2013;73:4406-4417. Published OnlineFirst May 14, 2013.

Updated version

Cited articles
Citing articles

E-mail alerts
Reprints and
Subscriptions
Permissions

Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-12-4297

This article cites 48 articles, 21 of which you can access for free at:
http://cancerres.aacrjournals.org/content/73/14/4406.full#ref-list-1
This article has been cited by 5 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/73/14/4406.full#related-urls

Sign up to receive free email-alerts related to this article or journal.
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at
pubs@aacr.org.
To request permission to re-use all or part of this article, contact the AACR Publications Department at
permissions@aacr.org.

Downloaded from cancerres.aacrjournals.org on September 2, 2017. ¬© 2013 American Association for Cancer Research.

